Advertisement

Topics

FDA to review Regeneron's sBLA for diabetic retinopathy injection

05:59 EDT 14 Sep 2018 | SmartBrief

Regeneron's supplemental biologics license application for Eylea, or aflibercept, injection for diabetic retinopathy treatmen -More

Original Article: FDA to review Regeneron's sBLA for diabetic retinopathy injection

NEXT ARTICLE

More From BioPortfolio on "FDA to review Regeneron's sBLA for diabetic retinopathy injection"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...